Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in
patients with resectable locally advanced rectal cancer. It is hypothesised that this may
enhance the pathological and imaging response rates whilst potentially reducing the relapse
rates. Participants will receive standard long course chemoradiotherapy (LCCRT) treatment
with radiotherapy and 5-fluorouracil (5 FU)/Capecitabine for 6 weeks, this then followed by 4
cycles of Avelumab and then surgical resection. The trial will measure disease response just
prior to surgery and participants will be followed up for a minimum of 18 months (from study
entry) and up to 42 months.